News
ASCO21: Novartis' prostate cancer radiotherapy extends survi...
Novartis' big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men with advanced prostate cancer and few treatment options li